Page 2 - Scientific Library

In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out of CD3 in human T-cells. The goal is to improve T-cell-based

Sequence engineering and chemical modification of CAS9 mRNA

For transgenesis and

Following the start of our recent collaboration with Phenocell, we’re pleased to be able to provide high quality Sebocytes developed from Human induced pluripotent stem cells (iPSC). Thanks to a perfectly

Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications

A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA enhance

Cell-based assays have become a classic way to monitor cells' reactions to a treatment or a specific stimulus. They involve a reporter construction and a detection system. The classic system is Firefly

Since the discovery of reprogramming factors in 2006 and the boom of CRISPR gene editing strategies, induced pluripotent stem cells (iPSC) have emerged as new cellular models. The development of 3D cell

Cell-based assays, screening for pathway activation or inhibition are classically done with promoter reporter clones expressing Firefly luciferase. Brighter, more stable, more sensitive, more convenient

Optimal knock-down can be done by a shRNA sequence that depends on the gene expression level and the cell type. Usually, 4 shRNA should be tested to find the one inducing a minimum of 70% increase of the

To overcome current cell model limitations, bit.bio have developed a new, innovative technology to reprogram human stem cells with precise control of transcription factor expression through iPSC engineering.